Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) – Analysts at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for Eyepoint Pharmaceuticals in a research report issued on Tuesday, March 12th. B. Riley analyst A. D’silva now forecasts that the company will earn ($0.18) per share for the quarter, down from their previous estimate of ($0.15). B. Riley also issued estimates for Eyepoint Pharmaceuticals’ Q4 2019 earnings at ($0.09) EPS, Q1 2020 earnings at ($0.09) EPS and Q2 2020 earnings at ($0.08) EPS.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%. The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $0.66 million.
Shares of EYPT opened at $2.47 on Thursday. Eyepoint Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $3.94. The firm has a market capitalization of $233.34 million, a P/E ratio of -4.26 and a beta of 2.01. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.37.
A number of hedge funds have recently bought and sold shares of EYPT. Virtu Financial LLC bought a new position in Eyepoint Pharmaceuticals during the fourth quarter valued at $31,000. Bank of New York Mellon Corp increased its position in Eyepoint Pharmaceuticals by 78.5% during the fourth quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock valued at $97,000 after acquiring an additional 22,645 shares during the last quarter. Regal Investment Advisors LLC increased its position in Eyepoint Pharmaceuticals by 27.3% during the fourth quarter. Regal Investment Advisors LLC now owns 69,950 shares of the company’s stock valued at $132,000 after acquiring an additional 15,000 shares during the last quarter. Private Advisor Group LLC bought a new position in Eyepoint Pharmaceuticals during the third quarter valued at $134,000. Finally, California Public Employees Retirement System bought a new position in Eyepoint Pharmaceuticals during the second quarter valued at $135,000. Institutional investors and hedge funds own 57.99% of the company’s stock.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.
Recommended Story: Liquidity
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.